

**Nazareno R. Suardi**

---

**Curriculum Vitae**

## Curriculum Vitae Dr. Nazareno Suardi

Nome: Nazareno Roberto Suardi

Data di nascita: 18/05/1978

Nazionalità: Italiana



### CONTATTI:

Lavoro:

Clinica Urologica  
IRCCS Ospedale San Martino  
8° piano Padiglione Monoblocco  
IRCCS Ospedale Policlinico San Martino  
Largo Rosanna Benzi 10  
16132 Genova  
e-mail: [nazarenoroberto.suardi@unige.it](mailto:nazarenoroberto.suardi@unige.it)

## TRAINING

- Liceo Classico (Completato nel luglio 1997) presso Istituto “Simone Weil”- Treviglio (BG) – Italy
  
- Corso di Laurea in Medicina e Chirurgia (Completata nel luglio 2003) - Università Vita – Salute San Raffaele - Milano – Votazione finale: 110/110
  
- Scuola di Specializzazione in Urologia (completata nel Novembre 2008) - University Vita – Salute San Raffaele – Milano – Votazione finale: 110/110
  
- Gennaio 2007 – Dicembre 2007: Fellowship Uro-Oncologica presso Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, QC, Canada (Dr. Pierre I. Karakiewicz)
  
- Gennaio 2008: European School of Urology Masterclass on Medical Treatments in Urologic Oncology
  
- Settembre 2008: European Residency Program (EUREP) Course – Praga
  
- Giugno 2009: European Board of Urology Examination in Athens, Greece – Certificazione di “Fellow of the European Board of Urology - FEBU”
  
- Luglio 2009: European School of Urology – Weill Cornell Masterclass in Urology, Salzburg, Austria
  
- Febbraio 2010 – Novembre 2010: Fellowship clinica in chirurgia urologica robotica c/o il Dipartimento di Urologia, dell’OLV Clinic in Aalst, Belgio sotto la direzione del Dr. Alexander Mottrie
  
- Lingue straniere:
  - Inglese: livello avanzato
  - Spagnolo: livello intermedio

## **ATTIVITA' LAVORATIVA**

- Dal Gennaio 2009 a febbraio 2012: Consulente del Dipartimento di Urologia dell'IRCCS San Raffaele. Durante questo periodo, ha ricoperto le medesime di Dirigente Medico.
- Dal 1 marzo 2012 al 31 maggio 2013: Dirigente Medico presso il Dipartimento di Urologia dell'IRCCS San Raffaele.
- Dal 1 giugno 2013 al 31 ottobre 2019: Dirigente Medico presso il Dipartimento di Urologia dell'IRCCS San Raffaele Turro.
- Dal 1 novembre 2019 ad oggi: Professore Associato per la Disciplina MED/24 Urologia presso l'Università degli Studi di Genova - Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate.
- Dal 1 novembre 2019 ad oggi: Dirigente Medico presso la Clinica Urologica dell'IRCCS San Martino di Genova.

## **POSIZIONE ATTUALE**

Dirigente Medico  
Clinica Urologica  
8° piano Padiglione Monoblocco  
IRCCS Ospedale Policlinico San Martino  
Largo Rosanna Benzi 10  
16132 Genova

Professore Associato – settore scientifico-disciplinare MED/24 Urologia  
Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate (DISC)  
Università degli Studi di Genova

**MEMBRO DELLE SEGUENTI SOCIETA' SCIENTIFICHE:**

- Società Italiana di Urologia (SIU)
- European Association of Urology (EAU)
- American Urological Association (AUA)
- ERUS Scientific Working Group

**ATTIVITA' DI INSEGNAMENTO:**

- Professore a Contratto - Corso di Laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell'Università Vita-Salute San Raffaele, Anno Accademico 2013-2014 - Corso Elettivo "Anatomia chirurgica e topografica di scavo pelvico e organi genitali maschili" dal 30-10-2013 al 27-11-2013
- Professore a Contratto - Corso di Laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell'Università Vita-Salute San Raffaele, Anno Accademico 2014-2015 - Corso Elettivo "Outcomes Research e Biostatistica applicata all'Urologia" dal 06-11-2014 al 04-12-2014
- Professore a Contratto - Corso di Laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell'Università Vita-Salute San Raffaele, Anno Accademico 2016-2017 - Corso Elettivo "Outcomes Research e Biostatistica applicata all'Urologia" dal 10-11-2016 al 31-10-2019
- Professore Associato per il Settore Scientifico Disciplinare MED/24 – Urologia preso il Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate – Università degli Studi di Genova

**PUBBLICAZIONI - OVERVIEW:**

- Number of published articles: 228 (PubMed search 23 aprile 2019)
- Total number of citations: 7959 (Scopus search 23 aprile 2019)
- h-Index: 49 (Scopus search 23 aprile 2019)

**ATTIVITA' EDITORIALE:**

- Editorial Board Member of the European Urology Editorial Board at Large dal 01-01-2009 a oggi
- Editorial Board Member of the European Urology Supplements Editorial Board at Large dal 01-01-2009 a oggi
- Editorial Board Member of the Journal "Advances in Urology" dal 10-03-2013 a oggi

- Member of the Editorial Committee of the Journal "Minerva Urologica e Nefrologica" dal 22-12-2014 a oggi

**ATTIVITA' DI REVIEWER:**

- Official journal reviewer for the Journal "European Urology" dal 09-09-2007 a oggi
- Official journal reviewer for the Journal "Journal of Urology" dal 17-04-2009 a oggi
- Official journal reviewer for the Journal "European Urology Supplements" dal 05-05-2009 a oggi
- Official journal reviewer for the Journal "BJU International" dal 10-05-2011 a oggi
- Official journal reviewer for the Journal "Journal of Endourology" dal 21-06-2012 a oggi
- Official journal reviewer for the Journal "British Medical Journal" dal 30-09-2013 a oggi
- Official journal reviewer for the Journal "Urology" dal 08-07-2016 a oggi

**PREMI E RICONOSCIMENTI:**

- Best Poster at the 2008 American Urological Association Annual Congress in Orlando, FL – May 17-22 2008: “THE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON THE RATE OF SUBSEQUENT NON-CANCER MORBIDITIES”.
- Best Poster at the European Association of Urology Annual Congress in Barcelona– April 16-20 2010: “THE YORK-MASON TECHNIQUE FOR RECTO-URINARY FISTULAS: A SINGLE-SURGEON 18-YEAR EXPERIENCE” – Abstract n. 213
- Best Poster at the 2010 European Association of Urology Annual Congress in Barcelona – April 16-20 2010: “THE ROLE OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH [11C]-CHOLINE PET/CT SCAN DETECTED NODAL RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMY” – Abstract n. 158
- Vincitore del Grant per “Giovani Ricercatori 2009” del Ministero della Salute per lo studio: “A PROSPECTIVE COMPARATIVE STUDY BETWEEN OPEN AND ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY FOR PATIENTS WITH ORGAN-CONFINED PROSTATE CANCER. IMPACT OF SURGICAL APPROACH ON ONCOLOGICAL AND FUNCTIONAL RESULTS , PERI-OPERATIVE PARAMETERS AND COSTS”.
- Best Poster at the 2012 American Urological Association Annual Congress in Atlanta, GA – May 19-23 2012: “Evaluation of lymph node recurrent prostate cancer with integrated [11C]choline PET/CT in patients with PSA failure after radical prostatectomy: Validation by histological analysis” – abstract n. 182.
- “Premio Bracci 2015” for the Best International Paper in Urology by an Italian Author in 2014 for the manuscript: “Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery after Radical Prostatectomy” published in European Urology.
- 02/08/2017: Conseguimento dell’Abilitazione Scientifica Nazionale a Professore di Seconda Facia – settore concorsuale 06/E2.
- Vincitore del Grant per “Giovani Ricercatori 2016” del Ministero della Salute per lo studio: “RETAGGING PATIENTS WITH RECURRENT PROSTATE CANCER AFTER DEFINITIVE THERAPY. PROSPECTIVE CLINICAL EVALUATION OF PET/MRI WITH 68GA-PSMA AND OF PET/MRI WITH THE NEW 68GA-BOMBESIN PET TRACER AND ANALYSIS OF A LESION-BASED APPROACH IN THE SETTING OF RECURRENCE PROSTATE CANCER.”.
- Vincitore del premio Italian Matula Award 2018 della Società Italiana di Urologia per il miglior curriculum scientifico italiano under 40. 91° Congresso SIU - Riccione, 13 ottobre 2018.

**PARTECIPAZIONE A CONGRESSI IN QUALITA' DI RELATORE O MODERATORE:**

- Invited speech: *"Sorveglianza attiva: quel che resta da chiarire"* – 84° Congresso Nazionale della Società Italiana di Urologia, Roma, 25 ottobre 2011.
- Invited speech: *"La sorveglianza attiva, una soluzione proponibile"* – Congresso di Urologia: Lo screening della patologia prostatica, Vicenza, 12 maggio 2012.
- Invited speech: *"Are there new laboratory markers"* – Global Congress on Prostate Cancer. Brussels, 30 giugno 2012.
- Invited speech: *"What topics need to be better elucidated in the area of urological robotic surgery? Non-oncologic topic"* – ERUS Course 4: How to improve the quality of reports of research in robotic urology : the search for evidence - 10<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), London, 26 settembre 2012.
- Invited speech: *"The role of surgery for M+, N+ prostate cancer."* – Insight on Genitourinary Cancers, Bari, 30 novembre 2012.
- Invited speech: *"Terapia medica dell'ipertrofia prostatica."* – 62° Congresso degli Urologi del Nord Italia – SUNI, Monastier di Treviso, 18 maggio 2013.
- Invited speech: *"Work-up diagnostico e terapeutico della neoplasia prostatica localizzata. Strategie terapeutiche: chirurgia"* – XXV Congresso Nazionale SIURO, Firenze, 9 giugno 2013.
- Invited speech: *"Carcinoma prostatico nel paziente ad alto rischio cardiovascolare: indicazioni terapeutiche a confronto: Prostatectomia radicale laparoscopica e robotica"* – Chirurgia Urologica nel Paziente Coronaropatico con Stent o a Rischio Stent: Gestione peri-Operatoria della Terapia Antiaggregante, Bergamo, 21 giugno 2013.
- Invited speech: *"Follow up from the Pasadena consensus conference on prostate cancer. What's new in robotic prostatectomy?"* – 10<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Stockholm, 4 settembre 2016.
- Invited speech: *"Terapia medica dell'ipertrofia prostatica: focus on silodosina."* – 7° Corso di Urologia Funzionale: Innervazione e Sistema Genitourinario, un Viaggio Guidato Andata e Ritorno dal Centro alla Periferia, Verona, 25 ottobre 2013.
- Invited speech: *"Aspetti clinico-diagnostici: PCA3."* – Focus on Tumore della Prostata, Genova, 23 novembre 2013.
- Invited speech: *"Prevention and management of erectile dysfunction following robot-assisted radical prostatectomy."* – Second daVinci Junior Users Meeting, Arezzo, 7 dicembre 2013.
- Invited speech: *"Best 2014 papers in robotic prostatectomy"* – Junior ERUS Meeting during the 11<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Amsterdam, 17 settembre 2014.
- Invited speech: *"La terapia Focale del CaP: energie e procedure, indicazioni e risultati"* – XVIII Corso di Urologia Generale, Robotica, Laparoscopica, Finalborgo, 17 ottobre 2014.
- Moderation in Abstract Poster Session n. 10: *"Prostate biopsy and outcomes"* at the 30<sup>th</sup> Annual Congress of the European Association of Urology, 21 marzo 2015, Madrid.
- Invited speech: *"BCG treatments for superficial bladder cancer"* – 16<sup>th</sup> International EAUN Meeting, Madrid, 21 marzo 2015.
- Invited speech: *"Ruolo della chirurgia nel trattamento della recidiva clinica del tumore prostatico"* – XXV Congresso Nazionale SIURO, Roma, 22 giugno 2015.
- Invited speech: *"Unmet needs in prostate cancer recurrence"* – Prostate Cancer: What's New, Bologna, 12 luglio 2015.
- Invited speech: *"Best 2015 papers in robotic prostatectomy"* – Junior ERUS Meeting during the 12<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Bilbao, 15 settembre 2015.
- Invited speech: *"Bladder cancer: clinical case discussion"* – AUA Corner, 88° Congresso Nazionale della Società Italiana di Urologia, Riccione, 11 ottobre 2015.
- Invited speech: *"Aspetti anestesilogici della chirurgia robotica in urologia"* – ERAS in Chirurgia Urologica LPS/Robotica, Milano, 3 novembre 2015.



- Invited speech: *“La terapia medica della neoplasia prostatica avanzata: LHRH agonisti”* – UROLOGIA Step by Step, Udine, 20 novembre 2015.
- Invited speech: *“Surgery in prostate cancer patients – a translational approach”* – Prostate Cancer Throughout the “Omic” era, Milano, 26 novembre 2015.
- Invited speech: *“Trattamento dei pazienti a rischio intermedio: chemioterapia vs. BCG”* – I Sabati dell’Urologia, Milano, 12 dicembre 2015.
- Invited speech: *“Oligometastatic disease equals non-metastatic disease. Definition of oligometastatic disease.”* – 31° Annual Congress of the European Association of Urology, Munich, 12 marzo 2016.
- Invited speech: *“The clinical consequences of PET signals after curative treatments”* – 31° Annual Congress of the European Association of Urology, Munich. 14 marzo 2016
- Moderation in Abstract Poster Session n. 31: *“Novel biomarkers for prostate cancer prediction”* at the 31<sup>th</sup> Annual Congress of the European Association of Urology, Munich, 13 marzo 2016,.
- Invited speech: *“Prostatectomia radicale robotica: abbiamo vinto la sfida?”* – USER Meeting in Urologia Robotica, Milano, 8 aprile 2016.
- Invited speech: *“Nerve sparing: erection recovery and rehabilitation after robotic radical prostatectomy.”* – RoboticAre Meeting, Arezzo, 14 aprile 2016.
- Invited speech: *“Robotic-assisted radical prostatectomy: scientific evidences and literature review.”* – RoboticAre Meeting, Arezzo, 14 aprile 2016.
- Invited speech: *“Tumore della prostata ad alto rischio: opzioni terapeutiche e risultati. Discussione di casi clinici.”* – 65° Congresso della Società degli Urologi del Nord Italia, Milano, 13 maggio 2016.
- Invited speech: *“Contemporary role of salvage lymphadenectomy in the management of recurrent prostate cancer”* – 13<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Milano, 16 settembre 2016.
- Invited speech: *“State of the art of minimally invasive surgery for benign prostatic obstruction”* – 6<sup>th</sup> International Meeting of Technology and Training in Endourology, Torino, 22 settembre 2016.
- Invited speech: *“The era of nomograms: assessing risk of nodal invasion in prostate and bladder cancer”* – Lymphadenectomy in Urological Surgery, technique and template: Myths and facts, Bergamo, 4 novembre 2016.
- Invited speech: *“La chirurgia robotica: le esigenze del chirurgo”* – Progetto educativo Lombardia Anestesia e Chirurgia: un percorso condiviso, Milano, 17 febbraio 2017
- Invited speech: *“Surgical approach to prostate cancer”* – 2017 Uro-Oncology Update, Ancona, 10 marzo 2017
- Moderation in Abstract Poster Session n. 60: *“Active surveillance for low-risk prostate cancer: What we still need to know?”* at the 30<sup>th</sup> Annual Congress of the European Association of Urology, 27 marzo 2017, London.
- Panelist – Thematic session: *“Lymph node surgery in uro-oncology: Semi-Live”* at the 30<sup>th</sup> Annual Congress of the European Association of Urology, 27 marzo 2017, London.
- Invited speech: *“Il carcinoma prostatico oligometastatico alla diagnosi: iter diagnostico e possibili strategie terapeutiche, quale ruolo per la chirurgia?”* - XXVIII Congresso Nazionale SIURO, Napoli, 22 aprile 2017
- Invited speech: *“Salvage Lymph Node Dissection for Recurrent Prostate Cancer”* – 5<sup>th</sup> World Robotis Surgery Event, June 15<sup>th</sup> 2017
- Invited speech: *“Update in salvage lymphadenectomy”* – 14<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Bruges. 26 Settembre 2017.
- Moderazione nella sessione *“Tumore della prostata: chirurgia di salvataggio dopo trattamento primario”*. 90° Congresso Annuale della Società Italiana di Urologia. Napoli, 10 ottobre 2017.
- Invited Speech: *“RM multiparametrica della prostata. Interpretare I dati in urologia: cosa vedere, perchè osservare”*. USER Meeting Napoli, 10 novembre 2017.

- Invited Speech: *"Salvage lymphadenectomy in the management of recurrent prostate cancer: robotics"*. 2018 Annual Meeting of the European Society of Oncological Urology (ESOU). Amsterdam, 27 gennaio 2018
- Invited Speech: *"Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer"* at the 2018 Annual Congress of the European Association of Urology, 16 marzo 2018, Copenhagen.
- Moderation in Abstract Poster Session n. 68: *"Prostate cancer staging: Imaging versus statistics – look or calculate?"* at the 2018 Annual Congress of the European Association of Urology, 19 marzo 2018, Copenhagen.
- Teacher at the course *"Laparoscopy in Urology"*. Dubai, 11-12 maggio 2018.
- Invited speech: *"Focus on analoghi e rischio cardiovascolare"*. 13° Congresso Nazionale Urop. Salerno, 25 maggio 2018
- Responsabile Scientifico e relatore al convegno: *"Tumore della prostata ad alto rischio: verso un percorso diagnostic-terapeutico individualizzato"*. Milano, 11 giugno 2018
- Invited speech: *"Salvage surgery and treatment of the primary in metastatic prostate cancer: need or search for an indication"* – 15<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Marseille. 7 Settembre 2018.
- Invited speech: *"Salvage lymphadenectomy: indications and results"* – 15<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), Marseille. 7 Settembre 2018.
- Invited speech: *"La linfadenectomia di salvataggio: come, quando e perchè?"* – Congresso MRI in prostate cancer. Milano, 22 febbraio 2019.
- Invited Speech: *"Novel imaging in prostatect cancer: improvement or waste of money?"* at the Plenary session n. 3 - 2019 Annual Congress of the European Association of Urology, 17 marzo 2019, Barcelona.
- Moderation in Abstract Poster Session n. 37: *"New modalities for staging of recurrent prostate cancer"* at the 2019 Annual Congress of the European Association of Urology, 17 marzo 2019, Barcelona.
- Invited speech: *"Radical cystectomy/multimodal conservative approach and radiotherapy alone and in combination treatment studies"* at the II° SIU updates ASCO-GU, 16 maggio 2019, Roma.
- Invited speech: *"PSMA targeted imaging and treatment in prostate cancer"* – 16<sup>th</sup> Meeting of the EAU Robotic Urology Section (ERUS), 12 Settembre 2019, Lisbon.
- Invited speech: *"Medicina di precision nel tumore della prostate: image-guided treatment nella terapia di salvataggio"*. 92° Congresso Annuale della Società Italiana di Urologia. Venezia, 13 ottobre 2019.

**ELENCO DELLE PUBBLICAZIONI (in ordine cronologico decrescente):**

- 1: Gaboardi F, Mantica G, Smelzo S, Pini G, Marchi D, Passaretti G, Saitta G, Rigatti L, **Suardi N**.  
Robotic-assisted laparoscopic pyeloplasty with the use of the Contour™ stent: description of the technique and analysis of outcomes after the first 30 cases.  
Cent European J Urol. 2019;72(1):51-53. doi: 10.5173/ceju.2018.1844.
- 2: Dell'Oglio P, Tian Z, Leyh-Bannurah SR, Larcher A, Mazzone E, Moschini M, Trudeau V, Stabile A, Gallina A, **Suardi N**, Capitanio U, Mottrie A, Briganti A, Montorsi F, Rochefort CM, Karakiewicz PI.  
Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy.  
Ann Surg Oncol. 2019 Mar 27. doi: 10.1245/s10434-019-07313-y.
- 3: Bravi CA, Tin A, Vertosick E, Mazzone E, Martini A, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, **Suardi N**, Gallina A, Briganti A, Montorsi F, Vickers A.  
The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.  
J Urol. 2019 Feb 7:101097JU0000000000000147. doi: 10.1097/JU.0000000000000147.
- 4: Saitta G, Becerra JEA, Del Álamo JF, González LL, Elbers JR, **Suardi N**, Gómez-Sancha F.  
'En Bloc' HoLEP with early apical release in men with benign prostatic hyperplasia.  
World J Urol. 2019 Feb 8. doi: 10.1007/s00345-019-02671-4.
- 5: Smelzo S, Mantica G, **Suardi N**, Passaretti G, De Marchi D, Pini G, Oreggia D, Gaboardi F.  
Robotic surgery in patients with achondroplastic dwarfism: evaluation of risks and issues in an anatomical challenging bilateral partial nephrectomy.  
J Robot Surg. 2019 Jan 23. doi: 10.1007/s11701-018-00904-z.
- 6: van Leeuwen FWB, Winter A, van Der Poel HG, Eiber M, **Suardi N**, Graefen M, Wawroschek F, Maurer T.  
Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer.  
Nat Rev Urol. 2019 Mar;16(3):159-171.
- 7: Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, **Suardi N**, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.  
Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.  
Clin Genitourin Cancer. 2019 Feb;17(1):72-78.
- 8: Fossati N, **Suardi N**, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.  
Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.  
Eur Urol. 2019 Jan;75(1):176-183.
- 9: Gaboardi F, Pini G, **Suardi N**, Montorsi F, Passaretti G, Smelzo S.  
Robotic laparoendoscopic single-site radical prostatectomy (R-LESS-RP) with daVinci Single-Site® platform. Concept and evolution of the technique following an IDEAL phase 1.  
J Robot Surg. 2019 Apr;13(2):215-226.
- 10: Dell'Oglio P, Stabile A, Dias BH, Gandaglia G, Mazzone E, Fossati N, Cucchiara V, Zaffuto E, Mirone V, **Suardi N**, Mottrie A, Montorsi F, Briganti A.

Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy.

World J Urol. 2019 Feb;37(2):221-234.

11: Bandini M, Fossati N, Gandaglia G, Preisser F, Dell'Oglio P, Zaffuto E, Stabile A, Gallina A, **Suardi N**, Shariat SF, Montorsi F, Karakiewicz PI, Briganti A.

Neoadjuvant and adjuvant treatment in high-risk prostate cancer.

Expert Rev Clin Pharmacol. 2018 Apr;11(4):425-438.

12: Gandaglia G, Zaffuto E, Fossati N, Bandini M, **Suardi N**, Mazzone E, Dell'Oglio P, Stabile A, Freschi M, Montorsi F, Briganti A. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.

BJU Int. 2018 Mar;121(3):421-427.

13: Nini A, Capitanio U, Larcher A, Dell'Oglio P, Dehò F, Suardi N, Muttin F, Carezzi C, Freschi M, Lucianò R, La Croce G, Briganti A, Colombo R, Salonia A, Castiglioni A, Rigatti P, Montorsi F, Bertini R.

Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium.

Eur Urol. 2018 May;73(5):793-799.

14: Dell'Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, **Suardi N**, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A.

New surgical approaches for clinically high-risk or metastatic prostate cancer.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1013-1031.

15: **Suardi N**, Montorsi F.

Salvage lymph node dissection: if yes, robotics?

BJU Int. 2017 Sep;120(3):304-305.

16: Fossati N, Di Trapani E, Gandaglia G, Dell'Oglio P, Umari P, Buffi NM, Guazzoni G, Mottrie A, Gaboardi F, Montorsi F, Briganti A, **Suardi N**.

Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons.

J Endourol. 2017 31(9):872-877

17: Varca V, Benelli A, Pietrantuono F, **Suardi N**, Gregori A, Gaboardi F.

A robotic needle driver to facilitate vesico-urethral anastomosis during laparoscopic radical prostatectomy.

Urologia. 2017 Jun 19;0. doi: 10.5301/uj.5000245. [Epub ahead of print]

18: Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M, Dell'Oglio P, **Suardi N**, Montorsi F, Karnes RJ, Briganti A.

Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.

Eur Urol. 2017 Dec;72(6):910-917.

19: Buffi NM, Lughezzani G, Hurle R, Lazzeri M, Taverna G, Bozzini G, Bertolo R, Checcucci E, Porpiglia F, Fossati N, Gandaglia G, Larcher A, **Suardi N**, Montorsi F, Lista G, Guazzoni G, Mottrie A.

Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions.

Eur Urol. 2017 Jun;71(6):945-951.

20: **Suardi N**, Briganti A, Gandaglia G, Fossati N, Montorsi F.

Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?

Eur Urol. 2017 May;71(5):693-694.

21: Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell'Oglio P, Moschini M, **Suardi N**, Dehò F, Montorsi F, Schiavina R, Mottrie A, Briganti A.

Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?

Urol Oncol. 2017 Apr;35(4):150.e9-150.e15.

22: Buffi NM, Lughezzani G, Hurle R, Lazzeri M, Taverna G, Bozzini G, Bertolo R, Checcucci E, Porpiglia F, Fossati N, Gandaglia G, Larcher A, **Suardi N**, Montorsi F, Lista G, Guazzoni G, Mottrie A.

Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: Nicolò Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions.

Eur Urol. 2017 Mar;71(3):e92-e93.

23: Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, **Suardi N**, Mirone V, Bandini M, Shariat SF, Karakiewicz PI, Montorsi F, Briganti A.

Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer.

J Urol. 2017 Mar;197(3 Pt 1):669-675.

24: Bianchi L, Gandaglia G, Fossati N, **Suardi N**, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.

Urologia. 2017 Feb 3;84(1):9-19.

25: Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Luzzago S, Zaffuto E, **Suardi N**, Damiano R, Shariat SF, Montorsi F, Briganti A.

Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy.

Clin Genitourin Cancer. 2017 Feb;15(1):67-71.

26: Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, **Suardi N**, Montorsi F, Briganti A, Rocco B, Mottrie A.

Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.

Eur Urol. 2017 Feb;71(2):249-256.

27: Pini G, Matin SF, **Suardi N**, Desai M, Gill I, Porter J, Stein RJ, Sotelo R, Gaboardi F, Porpiglia F. Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal.

Minerva Urol Nefrol. 2017 Feb;69(1):38-55.

28: Dell'Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, **Suardi N**, Montorsi F, Briganti A.

The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.

Prostate. 2017 Feb;77(3):263-273.

29: Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, Shariat SF, **Suardi N**, Montorsi F, Briganti A, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI.

A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients. World J Urol. 2017 Feb;35(2):189-197.

30: Larcher A, Dell'Oglio P, Fossati N, Nini A, Muttin F, **Suardi N**, De Cobelli F, Salonia A, Briganti A, Zhang X, Montorsi F, Bertini R, Capitanio U.

When to perform preoperative chest computed tomography for renal cancer staging.  
BJU Int. 2016 Sep 29. doi: 10.1111/bju.13670. [Epub ahead of print]

31: Montorsi F, Gandaglia G, Fossati N, **Suardi N**, Pultrone C, De Groote R, Dovey Z, Umari P, Gallina A, Briganti A, Mottrie A. Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. Eur Urol. 2016 Sep 3. pii: S0302-2838(16)30524-3. doi: 10.1016/j.eururo.2016.08.051. [Epub ahead of print]

32: Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, **Suardi N**, Mottrie A, Mirone V, Montorsi F, Briganti A.  
Rationale for local treatment in the management of metastatic prostate cancer.  
Curr Opin Support Palliat Care. 2016 Sep;10(3):266-72.

33: Gandaglia G, Fossati N, **Suardi N**, Montorsi F, Briganti A.  
STAMPEDE trial and patients with non-metastatic prostate cancer.  
Lancet. 2016 Jul 16;388(10041):234-5.

34: Giusti G, Proietti S, Villa L, Cloutier J, Rosso M, Gadda GM, Doizi S, **Suardi N**, Montorsi F, Gaboardi F, Traxer O.  
Current Standard Technique for Modern Flexible Ureteroscopy: Tips and Tricks.  
Eur Urol. 2016 Jul;70(1):188-194.

35: Moschini M, Karnes RJ, **Suardi N**, Bianchi M, Pellucchi F, Rocchini L, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R.  
Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.  
Clin Genitourin Cancer. 2016 Jun;14(3):e245-50.

36: Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, **Suardi N**, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.  
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.  
Eur Urol. 2016 Jun;69(6):1142-8.

37: Gandaglia G, Lista G, Fossati N, **Suardi N**, Gallina A, Moschini M, Bianchi L, Rossi MS, Schiavina R, Shariat SF, Salonia A, Montorsi F, Briganti A.  
Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.  
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):185-90.

38: Dell'Oglio P, **Suardi N**.  
Re: Acute Toxicity and Quality of Life After Dose-intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.  
Eur Urol. 2016 May;69(5):966.

39: Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, **Suardi N**, Briganti A, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M.  
A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.  
Eur Urol. 2016 May;69(5):788-94.

40: Dell'Oglio P, **Suardi N**, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.  
Predicting survival of men with recurrent prostate cancer after radical prostatectomy.  
Eur J Cancer. 2016 Feb;54:27-34.

- 41: **Suardi N**, Dell'Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, Shariat SF, Guazzoni G, Gaboardi F, Montorsi F, Briganti A.  
Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups.  
Urol Oncol. 2016 Feb;34(2):57.e1-7.
- 42: Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, **Suardi N**, Briganti A, Montorsi F, Cathelineau X.  
A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatin-based chemotherapy.  
World J Urol. 2016 Feb;34(2):207-13.
- 43: Nini A, Gandaglia G, Fossati N, **Suardi N**, Cucchiara V, Dell'Oglio P, Cazzaniga W, Luzzago S, Montorsi F, Briganti A.  
Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.  
Eur Urol. 2015 Nov;68(5):777-84.
- 44: Sammon JD, Abdollah F, D'Amico A, Gettman M, Haese A, **Suardi N**, Vickers A, Trinh QD.  
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.  
Eur Urol. 2015 Nov;68(5):756-65.
- 45: Gallina A, Bianchi M, Gandaglia G, Cucchiara V, **Suardi N**, Montorsi F, Briganti A.  
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.  
Eur Urol. 2015 Nov;68(5):750-3.
- 46: Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, **Suardi N**, Chun FK, Montorsi F, Graefen M, Briganti A.  
Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.  
Prostate. 2015 Sep;75(13):1484-91.
- 47: Moschini M, Gandaglia G, **Suardi N**, Fossati N, Cucchiara V, Damiano R, Cantiello F, Shariat SF, Montorsi F, Briganti A.  
Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. Int J Urol. 2015 Jun;22(6):555-61.
- 48: Gandaglia G, **Suardi N**, Cucchiara V, Bianchi M, Shariat SF, Roupret M, Salonia A, Montorsi F, Briganti A.  
Penile rehabilitation after radical prostatectomy: does it work? Transl Androl Urol. 2015 Apr;4(2):110-23.
- 49: Gandaglia G, Ploussard G, Isbarn H, **Suardi N**, De Visschere PJ, Futterer JJ, Ghadjar P, Massard C, Ost P, Sooriakumaran P, Surcel CI, van der Bergh RC, Montorsi F, Ficarra V, Giannarini G, Briganti A; Prostate Cancer Working Group of Young Academic Urologists Working Party of European Association of Urology. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.  
Urol Oncol. 2015 Apr;33(4):164.e1-9.
- 50: **Suardi N**, Cozzarini C, Montorsi F, Briganti A.  
Reply to Bernardino De Bari, Stefano Arcangeli, and Filippo Alongi's letter to the editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014;65:546-51.  
Eur Urol. 2015 Feb;67(2):e27-8.

51: Abdollah F, Gandaglia G, **Suardi N**, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, Shariat SF, Montorsi F, Briganti A. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. *Eur Urol.* 2015 Feb;67(2):212-9.

52: **Suardi N**, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.

Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

*Eur Urol.* 2015 Feb;67(2):299-309.

53: Larcher A, Fossati N, Mistretta F, Lughezzani G, Lista G, Dell'Oglio P, Abrate A, Sun M, Karakiewicz P, **Suardi N**, Lazzeri M, Montorsi F, Guazzoni G, Buffi N.

Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses.

*Urol Oncol.* 2015 Jan;33(1):22.e1-22.e9.

54: Abdollah F, Karnes RJ, **Suardi N**, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, Briganti A. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

*J Clin Oncol.* 2014 Dec 10;32(35):3939-47.

55: Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, **Suardi N**, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N.

Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.

*Eur Urol.* 2014 Dec;66(6):1024-30.

56: Gandaglia G, Gallina A, **Suardi N**, Abdollah F, Passoni N, Bianchi M, Zaffuto E, Nini A, Vizziello D, Salonia A, Montorsi F, Briganti A. Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy.

*Int J Impot Res.* 2014 Nov-Dec;26(6):201-4.

57: **Suardi N**, Larcher A, Haese A, Ficarra V, Govorov A, Buffi NM, Walz J, Rocco B, Borghesi M, Steuber T, Pini G, Briganti A, Mottrie AM, Guazzoni G, Montorsi F, Pushkar D, Van Der Poel H; EAU Young Academic Urologists–Robotic Section.

Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.

*Eur Urol.* 2014 Oct;66(4):635-43.

58: Salonia A, Clementi MC, Ventimiglia E, Colicchia M, Capogrosso P, Castiglione F, Castagna G, Boeri L, **Suardi N**, Cantiello F, Damiano R, Montorsi F.

Prevalence and predictors of concomitant low sexual desire/interest and new-onset erectile dysfunction - a picture from the everyday clinical practice. *Andrology.* 2014 Sep;2(5):702-8.

59: Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, **Suardi N**, Dell'Oglio P, Freschi M, Montorsi F, Briganti A. The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.

*Urology.* 2014 Sep;84(3):634-41.

60: Capitanio U, **Suardi N**, Matloob R, Roscigno M, Abdollah F, Di Trapani E, Moschini M, Gallina A, Salonia A, Briganti A, Montorsi F, Bertini R.

Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). *BJU Int.* 2014 Aug;114(2):210-5.



- 61: Gandaglia G, Giannarini G, **Suardi N**, Montorsi F, Briganti A.  
Will active surveillance for clinically localized prostate cancer survive in the era of individualized medicine?  
Eur Urol. 2014 Aug;66(2):186-7.
- 62: Gandaglia G, **Suardi N**, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, Shariat S, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A.  
How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center.  
J Endourol. 2014 Jul;28(7):792-800.
- 63: Moschini M, **Suardi N**, Pellucchi F, Rocchini L, La Croce G, Capitanio U, Briganti A, Damiano R, Montorsi F, Colombo R. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.  
Anticancer Res. 2014 Jun;34(6):3225-30.
- 64: Giannarini G, **Suardi N**, Briganti A.  
Re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al.  
A multinational, multi-institutional study comparing positive surgical margin rates among 22,393 open, laparoscopic, and robot-assisted radical prostatectomy patients.  
Eur Urol. 2014 Jun;65(6):e89-90.
- 65: **Suardi N**, Gandaglia G, Nini A, Montorsi F, Pellucchi F, Agostini A, Rigatti P.  
Effects of Difaprost® on voiding dysfunction, histology and inflammation markers in patients with benign prostatic hyperplasia who are candidates for surgical treatment.  
Minerva Urol Nefrol. 2014 Jun;66(2):119-25.
- 66: De Bari B, Alongi F, Buglione M, Camprostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, **Suardi N**, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jereczek-Fossa BA.  
Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.  
Crit Rev Oncol Hematol. 2014 Apr;90(1):24-35.
- 67: Dell'Oglio P, Abdollah F, **Suardi N**, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, Shariat S, Montorsi F, Briganti A.  
External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy.  
J Endourol. 2014 Apr;28(4):416-23.
- 68: Abdollah F, Karnes RJ, **Suardi N**, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.  
Eur Urol. 2014 Mar;65(3):554-62.
- 69: **Suardi N**, Gallina A, Lista G, Gandaglia G, Abdollah F, Capitanio U, Dell'Oglio P, Nini A, Salonia A, Montorsi F, Briganti A.  
Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.  
Eur Urol. 2014 Mar;65(3):546-51.
- 70: Briganti A, **Suardi N**, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F.  
Predicting the risk of bone metastasis in prostate cancer.  
Cancer Treat Rev. 2014 Feb;40(1):3-11.

71: Abdollah F, **Suardi N**, Capitanio U, Matloob R, Fossati N, Castiglione F, Di Trapani E, Di Trapani D, Russo A, Carenci C, Montorsi F, Rigatti P, Bertini R.

The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.

Urol Oncol. 2014 Jan;32(1):43.e9-16.

72: Passoni NM, **Suardi N**, Abdollah F, Picchio M, Giovacchini G, Messa C, Freschi M, Montorsi F, Briganti A. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2014 Jan;32(1):38.e9-16.

73: Passoni NM, Abdollah F, **Suardi N**, Gallina A, Bianchi M, Tutolo M, Fossati N, Gandaglia G, Salonia A, Freschi M, Rigatti P, Montorsi F, Briganti A.

Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.

Urol Oncol. 2014 Jan;32(1):29.e21-8.

74: Abdollah F, Cozzarini C, Sun M, **Suardi N**, Gallina A, Passoni NM, Bianchi M, Tutolo M, Fossati N, Nini A, Dell'oglio P, Salonia A, Karakiewicz P, Montorsi F, Briganti A.

Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol. 2013 Nov;109(2):211-6.

75: Abdollah F, Sun M, **Suardi N**, Gallina A, Capitanio U, Bianchi M, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification.

Urol Oncol. 2013 Nov;31(8):1497-503.

76: Abdollah F, Boorjian S, Cozzarini C, **Suardi N**, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.

Eur Urol. 2013 Oct;64(4):557-64.

77: Abdollah F, **Suardi N**, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.

BJU Int. 2013 Aug;112(4):E234-42.

78: Ficarra V, Borghesi M, **Suardi N**, De Naeyer G, Novara G, Schattelman P, De Groot R, Carpentier P, Mottrie A.

Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP).

BJU Int. 2013 Aug;112(3):338-45.

79: Capitanio U, Abdollah F, Matloob R, **Suardi N**, Castiglione F, Di Trapani E, Capogrosso P, Gallina A, Dell'Oglio P, Briganti A, Salonia A, Montorsi F, Bertini R.

When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up.

BJU Int. 2013 Jul;112(2):E59-66.

80: Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, **Suardi N**, Castiglione F, Briganti A, Cantiello F, Damiano R, Montorsi F, Salonia A.

One patient out of four with newly diagnosed erectile dysfunction is a young man--worrisome picture from the everyday clinical practice.

J Sex Med. 2013 Jul;10(7):1833-41.

81: Abdollah F, **Suardi N**, Gallina A, Bianchi M, Tutolo M, Passoni N, Fossati N, Sun M, dell'Oglio P, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A.

Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center.

Ann Oncol. 2013 Jun;24(6):1459-66.

82: Briganti A, Bianchi M, Sun M, Suardi N, Gallina A, Abdollah F, Bertini R, Colombo R, Girolamo VD, Salonia A, Scattoni V, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F.

Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre.

BJU Int. 2013 Jun;111(8):1222-30.

83: Abdollah F, **Suardi N**, Cozzarini C, Gallina A, Capitanio U, Bianchi M, Sun M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A.

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis.

Eur Urol. 2013 Jun;63(6):998-1008.

84: Capitanio U, Abdollah F, Matloob R, Salonia A, **Suardi N**, Briganti A, Careni C, Rigatti P, Montorsi F, Bertini R.

Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy.

Int J Urol. 2013 Jun;20(6):572-9.

85: Abdollah F, Sun M, **Suardi N**, Gallina A, Tutolo M, Passoni N, Bianchi M, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A.

A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy.

BJU Int. 2013 May;111(6):905-13.

86: **Suardi N**, Moschini M, Gallina A, Gandaglia G, Abdollah F, Capitanio U, Bianchi M, Tutolo M, Passoni N, Salonia A, Hedlund P, Rigatti P, Montorsi F, Briganti A.

Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.

BJU Int. 2013 May;111(5):717-22.

87: Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, **Suardi N**, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

BJU Int. 2013 May;111(5):723-30.

88: Ficarra V, Wiklund PN, Rochat CH, Dasgupta P, Challacombe BJ, Sooriakumaran P, Siemer S, **Suardi N**, Novara G, Mottrie A.

The European Association of Urology Robotic Urology Section (ERUS) survey of robot-assisted radical prostatectomy (RARP).

BJU Int. 2013 Apr;111(4):596-603.

89: Gandaglia G, Albersen M, **Suardi N**, Gallina A, Abdollah F, Castiglione F, Capitanio U, Salonia A, Rigatti P, Hedlund P, Montorsi F, Briganti A.

Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.

Int J Urol. 2013 Apr;20(4):413-9.

90: Salonia A, Abdollah F, Capitanio U, **Suardi N**, Gallina A, Castagna G, Clementi MC, Briganti A, Rigatti P, Montorsi F.

Circulating sex steroids and prostate cancer: introducing the time-dependency theory.

World J Urol. 2013 Apr;31(2):267-73.

91: Salonia A, Abdollah F, Capitanio U, Gallina A, **Suardi N**, Briganti A, Zanni G, Ferrari M, Castiglione F, Clementi MC, Rigatti P, Montorsi F.

Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol. 2013 Apr;31(2):275-80.

92: Capitanio U, **Suardi N**, Matloob R, Abdollah F, Castiglione F, Briganti A, Carezzi C, Roscigno M, Montorsi F, Bertini R.

Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. BJU Int. 2013 Mar;111(3):412-8.

93: Briganti A, **Suardi N**, Gallina A, Abdollah F, Montorsi F.

Pelvic lymph node dissection in prostate cancer: the mystery is taking shape.

Eur Urol. 2013 Mar;63(3):459-61.

94: Villa L, Capitanio U, Briganti A, Abdollah F, **Suardi N**, Salonia A, Gallina A, Freschi M, Russo A, Castiglione F, Bianchi M, Rigatti P, Montorsi F, Scattoni V.

The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.

J Urol. 2013 Mar;189(3):854-9.

95: Colombo R, Rocchini L, **Suardi N**, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F.

Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.

Eur Urol. 2013 Jan;63(1):e7-8.

96: Tutolo M, Briganti A, **Suardi N**, Gallina A, Abdollah F, Capitanio U, Bianchi M, Passoni N, Nini A, Fossati N, Rigatti P, Montorsi F.

Optimizing postoperative sexual function after radical prostatectomy.

Ther Adv Urol. 2012 Dec;4(6):347-65.

97: Colombo R, Rocchini L, **Suardi N**, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F.

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.

Eur Urol. 2012 Nov;62(5):797-802.

98: Gandaglia G, **Suardi N**, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, Bianchi M, Chun FK, Hansen J, Rigatti P, Montorsi F, Briganti A.

Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy.

J Sex Med. 2012 Aug;9(8):2187-94.

99: Abdollah F, Sun M, **Suardi N**, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni N, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A; National Comprehensive Cancer Network. National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer.

J Urol. 2012 Aug;188(2):423-8.

100: Passoni NM, Di Trapani E, **Suardi N**, Gallina A, Abdollah F, Bianchi M, Picchio M, Giovacchini G, Messa C, Rigatti P, Montorsi F, Briganti A.

Clinical and diagnostic assessment for therapeutic decisions in prostate cancer.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):321-30.

101: Salonia A, Gallina A, Abdollah F, Briganti A, Capitanio U, **Suardi N**, Ferrari M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F.

Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

World J Urol. 2012 Aug;30(4):533-9.

102: Gallina A, Maccagnano C, **Suardi N**, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8.

103: Salonia A, Abdollah F, Capitanio U, **Suardi N**, Briganti A, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F.

Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.

Clin Cancer Res. 2012 Jul 1;18(13):3648-57.

104: Abdollah F, Sun M, **Suardi N**, Gallina A, Bianchi M, Tutolo M, Passoni N, Tian Z, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, Briganti A.

Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses.

Eur Urol. 2012 Jul;62(1):42-52.

105: Briganti A, Abdollah F, Nini A, **Suardi N**, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F.

Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.

Eur Urol. 2012 Jun;61(6):1132-8.

106: Abdollah F, Cozzarini C, **Suardi N**, Gallina A, Capitanio U, Bianchi M, Tutolo M, Salonia A, La Macchia M, Di Muzio N, Rigatti P, Montorsi F, Briganti A.

Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):624-9.

107: Briganti A, Tutolo M, **Suardi N**, Gallina A, Abdollah F, Capitanio U, Freschi M, Bianchi M, Salonia A, Colombo R, Rigatti P, Montorsi F. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. *Prostate*. 2012 Jun 1;72(8):925-30.

108: Briganti A, Capitanio U, Abdollah F, Gallina A, **Suardi N**, Bianchi M, Tutolo M, Salonia A, Freschi M, Rigatti P, Montorsi F.  
Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. *Prostate*. 2012 Apr;72(5):499-506.

109: Capitanio U, Matloob R, **Suardi N**, Abdollah F, Castiglione F, Di Trapani D, Russo A, Briganti A, Carezzi C, Salonia A, Montorsi F, Rigatti P, Bertini R.  
The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. *Urologia*. 2012 Apr-Jun;79(2):109-15.

110: Capitanio U, **Suardi N**, Briganti A, Gallina A, Abdollah F, Lughezzani G, Salonia A, Freschi M, Montorsi F.  
Influence of obesity on tumour volume in patients with prostate cancer. *BJU Int*. 2012 Mar;109(5):678-84.

111: Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, **Suardi N**, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F.  
Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. *Eur Urol*. 2012 Mar;61(3):480-7.

112: Gallina A, Ferrari M, **Suardi N**, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Saccà A, Salonia A, Rigatti P, Montorsi F, Briganti A.  
Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? *J Sex Med*. 2012 Mar;9(3):903-8.

113: **Suardi N**, Gallina A, Capitanio U, Salonia A, Lughezzani G, Freschi M, Motttrie A, Rigatti P, Montorsi F, Briganti A. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. *Cancer*. 2012 Feb 15;118(4):973-80.

114: Briganti A, Di Trapani E, Abdollah F, Gallina A, **Suardi N**, Capitanio U, Tutolo M, Passoni N, Salonia A, DiGirolamo V, Colombo R, Guazzoni G, Rigatti P, Montorsi F.  
Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy. *J Sex Med*. 2012 Feb;9(2):608-17.

115: Gandaglia G, **Suardi N**, Gallina A, Capitanio U, Abdollah F, Salonia A, Nava L, Colombo R, Guazzoni G, Rigatti P, Montorsi F, Briganti A.  
Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. *J Urol*. 2012 Feb;187(2):569-74.

116: Briganti A, **Suardi N**, Capogrosso P, Passoni N, Freschi M, di Trapani E, Gallina A, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Salonia A, Da Pozzo LF, Montorsi F, Rigatti P.  
Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. *Prostate*. 2012 Feb 1;72(2):186-92.

117: Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, Pellucchi F, **Suardi N**, Abdollah F, Montorsi F, Rigatti P, Scattoni V.

Prostate saturation biopsy following a first negative biopsy: state of the art.

Urol Int. 2012;89(2):126-35.

118: **Suardi N**, Ficarra V, Willemsen P, De Wil P, Gallina A, De Naeyer G, Schatteman P, Montorsi F, Carpentier P, Mottrie A. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.

Urology. 2012 Jan;79(1):133-8.

119: Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, **Suardi N**, Capitanio U, Salonia A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.

Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy.

BJU Int. 2011 Dec;108(11):1769-75.

120: Salonia A, Gallina A, Briganti A, **Suardi N**, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.

Cancer. 2011 Nov 15;117(22):5029-38.

121: Rigatti P, **Suardi N**, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Eur Urol. 2011 Nov;60(5):935-43.

122: Salonia A, Gallina A, Briganti A, Abdollah F, **Suardi N**, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F.

Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.

Cancer. 2011 Sep 1;117(17):3953-62.

123: Capitanio U, **Suardi N**, Montorsi F, Briganti A.

Editorial Comment to Risk factors for pelvic lymphoceles post-radical prostatectomy.

Int J Urol. 2011 Sep;18(9):644-5.

124: Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, **Suardi N**, Gallina A, Capitanio U, Freschi M, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.

BJU Int. 2011 Aug;108(3):366-71.

125: Abdollah F, Briganti A, **Suardi N**, Castiglione F, Gallina A, Capitanio U, Montorsi F. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol. 2011 Aug;52(8):507-16.

126: **Suardi N**, Briganti A, Salonia A, Rigatti P.

Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.

Curr Opin Urol. 2011 May;21(3):237-40.

127: Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, **Suardi N**, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M.

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.

Eur Urol. 2011 May;59(5):832-40.

128: Salonia A, Gallina A, Briganti A, Zanni G, **Suardi N**, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

BJU Int. 2011 Apr;107(8):1243-9.

129: Capitanio U, Pellucchi F, Gallina A, Briganti A, **Suardi N**, Salonia A, Abdollah F, Di Trapani E, Jeldres C, Cestari A, Karakiewicz PI, Montorsi F.

How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications.

BJU Int. 2011 Apr;107(7):1095-101.

130: Briganti A, Gallina A, **Suardi N**, Capitanio U, Tutolo M, Bianchi M, Salonia A, Colombo R, Di Girolamo V, Martinez-Salamanca JI, Guazzoni G, Rigatti P, Montorsi F.

What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy?

J Sex Med. 2011 Apr;8(4):1210-7.

131: Abdollah F, Novara G, Briganti A, Scattoni V, Raber M, Roscigno M, **Suardi N**, Gallina A, Artibani W, Ficarra V, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology. 2011 Apr;77(4):921-5.

132: Abdollah F, Briganti A, **Suardi N**, Gallina A, Capitanio U, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?

Prostate Cancer Prostatic Dis. 2011 Mar;14(1):74-8.

133: Capitanio U, Briganti A, **Suardi N**, Gallina A, Salonia A, Freschi M, Rigatti P, Montorsi F.

When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy?

Int J Urol. 2011 Feb;18(2):148-53.

134: Capitanio U, **Suardi N**.

Prostate cancer in 2010: GSU: misclassification or biological progression?

Nat Rev Urol. 2011 Feb;8(2):65-6.

135: Gallina A, Briganti A, **Suardi N**, Capitanio U, Abdollah F, Zanni G, Salonia A, Rigatti P, Montorsi F. Surgery and erectile dysfunction.

Arch Esp Urol. 2010 Oct;63(8):640-8.

136: Capitanio U, Briganti A, Gallina A, **Suardi N**, Karakiewicz PI, Montorsi F, Scattoni V.

Predictive models before and after radical prostatectomy.

Prostate. 2010 Sep 1;70(12):1371-8.

137: Briganti A, Gallina A, **Suardi N**, Capitanio U, Tutolo M, Bianchi M, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F.

Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification.



J Sex Med. 2010 Jul;7(7):2521-31.

138: **Suardi N**, Briganti A, Gallina A, Salonia A, Karakiewicz PI, Capitanio U, Freschi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int. 2010 Jun;105(11):1548-52.

139: Briganti A, Passoni N, Ferrari M, Capitanio U, **Suardi N**, Gallina A, Da Pozzo LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P, Montorsi F.

When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.

Eur Urol. 2010 Apr;57(4):551-8.

140: Bhojani N, Capitanio U, **Suardi N**, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):342-8.

141: **Suardi N**.

Editorial comment. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

J Urol. 2010 Feb;183(2):545.

142: Porter CR, **Suardi N**, Capitanio U, Hutterer GC, Kodama K, Gibbons RP, Correa R Jr, Perrotte P, Montorsi F, Karakiewicz PI.

A nomogram predicting prostate cancer-specific mortality after radical prostatectomy.

Urol Int. 2010;84(2):132-40.

143: **Suardi N**.

The selection of patients for active surveillance: could it be perfect?

Eur Urol. 2009 Dec;56(6):899-900.

144: Salonia A, Matloob R, Gallina A, Abdollah F, Saccà A, Briganti A, **Suardi N**, Colombo R, Rocchini L, Guazzoni G, Rigatti P, Montorsi F.

Are infertile men less healthy than fertile men? Results of a prospective case-control survey.

Eur Urol. 2009 Dec;56(6):1025-31.

145: Salonia A, Zanni G, Gallina A, Briganti A, Saccà A, **Suardi N**, Matloob R, Da Pozzo LF, Bertini R, Colombo R, Rigatti P, Montorsi F.

Unsuccessful investigation of preoperative sexual health issues in the prostate cancer "couple": results of a real-life psychometric survey at a major tertiary academic center.

J Sex Med. 2009 Dec;6(12):3347-55.

146: Karakiewicz PI, **Suardi N**, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ.

Conditional survival predictions after nephrectomy for renal cell carcinoma.

J Urol. 2009 Dec;182(6):2607-12.

147: Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewicz P, **Suardi N**, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F.

Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer.  
Urology. 2009 Nov;74(5):1070-4.

148: Jeldres C, Cardinal H, Duclos A, Shariat SF, **Suardi N**, Capitanio U, Hébert MJ, Karakiewicz PI. Prediction of delayed graft function after renal transplantation.  
Can Urol Assoc J. 2009 Oct;3(5):377-82.

149: Salonia A, Gallina A, Matloob R, Rocchini L, Saccà A, Abdollah F, Colombo R, **Suardi N**, Briganti A, Guazzoni G, Rigatti P, Montorsi F.  
Is sperm banking of interest to patients with nongerm cell urological cancer before potentially fertility damaging treatments?  
J Urol. 2009 Sep;182(3):1101-7.

150: **Suardi N**, Gallina A, Salonia A, Briganti A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.  
Open prostatectomy and the evolution of HoLEP in the management of benign prostatic hyperplasia.  
Minerva Urol Nefrol. 2009 Sep;61(3):301-8.

151: Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F.  
Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.  
Int J Urol. 2009 Aug;16(8):676-81.

152: Jeldres C, Bensalah K, Capitanio U, Zini L, Perrotte P, **Suardi N**, Tostain J, Valeri A, Descotes JL, Rambeaud JJ, de La Taille A, Salomon L, Abbou C, Patard JJ, Karakiewicz PI.  
Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy.  
BJU Int. 2009 Jun;103(12):1632-5.

153: Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, **Suardi N**, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F.  
Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.  
J Urol. 2009 Jun;181(6):2482-9.

154: Svatek RS, Jeldres C, Karakiewicz PI, **Suardi N**, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF.  
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.  
Prostate. 2009 Jun 1;69(8):886-94.

155: Jeldres C, Patard JJ, Capitanio U, Perrotte P, **Suardi N**, Crepel M, Ficarra V, Cindolo L, de La Taille A, Tostain J, Pfister C, Albouy B, Colombel M, Méjean A, Lang H, Jacqmin D, Bernhard JC, Ferrière JM, Bensalah K, Karakiewicz PI.  
Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics. Urology. 2009 Jun;73(6):1300-5.

156: Capitanio U, Perrotte P, Zini L, **Suardi N**, Antebi E, Cloutier V, Jeldres C, Shariat SF, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI.  
Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort. Urology. 2009 Jun;73(6):1323-7.

157: Capitanio U, **Suardi N**, Shariat SF, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int.* 2009 May;103(10):1359-62.

158: Da Pozzo LF, Cozzarini C, Briganti A, **Suardi N**, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. *Eur Urol.* 2009 May;55(5):1003-11.

159: Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, **Suardi N**, Cestari A, Guazzoni G, Salonia A, Montorsi F. The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. *Int J Urol.* 2009 May;16(5):526-9.

160: Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, **Suardi N**, Cestari A, Guazzoni G, Salonia A, Montorsi F. Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer. *Urology.* 2009 May;73(5):1087-91.

161: Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer.* 2009 Mar 15;115(6):1224-33.

162: Chun FK, **Suardi N**, Capitanio U, Jeldres C, Ahyai S, Graefen M, Haese A, Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz PI. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. *Eur Urol.* 2009 Mar;55(3):617-28-6.

163: Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, **Suardi N**, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int.* 2009 Feb;103(3):307-11.

164: Jeldres C, **Suardi N**, Perrotte P, Capitanio U, Walz J, Hutterer GC, Saad F, Valiquette L, Graefen M, Widmer H, Karakiewicz PI. Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. *Can Urol Assoc J.* 2009 Feb;3(1):13-21.

165: Bhojani N, Ahyai S, Graefen M, Capitanio U, **Suardi N**, Shariat SF, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz PI. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. *Eur J Surg Oncol.* 2009 Feb;35(2):123-8.

166: Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, **Suardi N**, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. *Eur Urol.* 2009 Feb;55(2):261-70.

167: Karakiewicz PI, **Suardi N**, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de la Taille A, Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valéri A, Descotes JL, Rambeaud JJ, Méjean A, Montorsi F, Bertini R, Patard JJ.

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. *Eur Urol.* 2009 Feb;55(2):287-95.

168: Bhojani N, Salomon L, Capitanio U, Suardi N, Shariat SF, Jeldres C, Zini L, Pharand D, Péloquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F, Karakiewicz PI. External validation of the updated partin tables in a cohort of French and Italian men.

*Int J Radiat Oncol Biol Phys.* 2009 Feb 1;73(2):347-52.

169: Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, **Suardi N**, Oya M, Shariat SF.

Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

*J Clin Oncol.* 2009 Feb 1;27(4):612-8.

170: **Suardi N**, Strada E, Colombo R, Freschi M, Salonia A, Lania C, Cestari A, Carmignani L, Guazzoni G, Rigatti P, Montorsi F.

Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience.

*BJU Int.* 2009 Jan;103(2):197-200.

171: **Suardi N**, Gallina A, Salonia A, Briganti A, Dehò F, Zanni G, Abdollah F, Naspro R, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome.

*Curr Opin Urol.* 2009 Jan;19(1):38-43.

172: Deho F, Gallina A, Salonia A, Briganti A, **Suardi N**, Zanni G, Guazzoni G, Rigatti P, Montorsi F. Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors.

*Curr Pharm Des.* 2009;15(30):3496-501.

173: Capitanio U, Perrotte P, Hutterer GC, **Suardi N**, Jeldres C, Shariat SF, Duclos A, Arjane P, Montorsi F, Karakiewicz PI.

Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men.

*Int J Urol.* 2009 Jan;16(1):91-5.

174: Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, **Suardi N**, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P.

Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study.

*Urology.* 2009 Jan;73(1):142-6.

175: Karakiewicz PI, Jeldres C, **Suardi N**, Hutterer GC, Perrotte P, Capitanio U, Ficarra V, Cindolo L, de La Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Schips L, Chautard D, Valeri A, Lechevallier E, Descots JL, Lang H, Mejean A, Verhoest G, Patard JJ.

Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.

Can Urol Assoc J. 2008 Dec;2(6):610-7.

176: Jeldres C, **Suardi N**, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI.

Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.

Eur Urol. 2008 Dec;54(6):1306-13.

177: **Suardi N**, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T, Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI.

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.

Cancer. 2008 Oct 15;113(8):2068-72.

178: Briganti A, Capitanio U, Chun FK, Gallina A, **Suardi N**, Salonia A, Da Pozzo LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz PI, Montorsi F, Rigatti P.

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.

Eur Urol. 2008 Oct;54(4):794-802.

179: Porter CR, **Suardi N**, Kodama K, Capitanio U, Gibbons RP, Correa R, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI.

A nomogram predicting metastatic progression after radical prostatectomy.

Int J Urol. 2008 Oct;15(10):889-94.

180: Bertini R, **Suardi N**, Marone EM, Roscigno M, Petralia G, Strada E, Cestari A, Arrighi G, Guazzoni G, Montorsi F, Chiesa R, Rigatti P.

Pregnant woman presenting with a gross retroperitoneal mass: surgical treatment with caval replacement.

Eur Urol. 2008 Sep;54(3):677-80.

181: Bhojani N, Perrotte P, Hutterer G, **Suardi N**, Jeldres C, Shariat SF, Capitanio U, Arjane P, Widmer H, Benard F, Peloquin F, Montorsi F, Karakiewicz P.

Body mass index and its association with genitourinary disorders in men undergoing prostate cancer screening.

J Sex Med. 2008 Sep;5(9):2141-51.

182: Karakiewicz PI, Bhojani N, Capitanio U, Reuther AM, **Suardi N**, Jeldres C, Pharand D, Pélouquin F, Perrotte P, Shariat SF, Klein EA.

External validation of the updated Partin tables in a cohort of North American men. J Urol. 2008 Sep;180(3):898-902.

183: Chun FK, Haese A, Ahyai SA, Walz J, **Suardi N**, Capitanio U, Graefen M, Erbersdobler A, Huland H, Karakiewicz PI.

Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.

Cancer. 2008 Aug 15;113(4):701-9.

184: Jeldres C, **Suardi N**, Capitanio U, Montorsi F, Shariat SF, Perrotte P, Peloquin F, Pharand D, Graefen M, Karakiewicz PI.

High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer.  
BJU Int. 2008 Aug;102(4):463-7.

185: Gallina A, **Suardi N**, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, Shariat SF, Widmer H, Arjane P, Péroquin F, Perrotte P, Karakiewicz PI.  
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.  
Int J Cancer. 2008 Aug 1;123(3):647-52.

186: Shariat SF, Karakiewicz PI, **Suardi N**, Kattan MW.  
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.  
Clin Cancer Res. 2008 Jul 15;14(14):4400-7.

187: Walz J, **Suardi N**, Shariat SF, Jeldres C, Perrotte P, Graefen M, Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz PI.  
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.  
BJU Int. 2008 Jul;102(1):33-8.

188: Jeldres C, **Suardi N**, Saad F, Montorsi F, Shariat SF, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI.  
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.  
Eur Urol. 2008 Jul;54(1):97-105.

189: Jeldres C, **Suardi N**, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI.  
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.  
Eur Urol. 2008 Jul;54(1):107-16.

190: Walz J, Shariat SF, **Suardi N**, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.  
BJU Int. 2008 Jun;101(11):1356-61.

191: Gallina A, Chun FK, **Suardi N**, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat SF, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.  
BJU Int. 2008 Jun;101(12):1513-8.

192: **Suardi N**, Scattoni V, Briganti A, Salonia A, Naspro R, Gallina A, Cestari A, Colombo R, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F.  
Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement.  
Eur Urol. 2008 Jun;53(6):1180-5.

193: Bhojani N, Jeldres C, Patard JJ, Perrotte P, **Suardi N**, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.  
Eur Urol. 2008 May;53(5):917-30.

- 194: Montorsi F, Naspro R, Salonia A, **Suardi N**, Briganti A, Zanoni M, Valenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia.  
J Urol. 2008 May;179(5 Suppl):S87-90.
- 195: Walz J, Montorsi F, Jeldres C, **Suardi N**, Shariat SF, Perrotte P, Arjane P, Graefen M, Pharand D, Karakiewicz PI.  
The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases.  
BJU Int. 2008 Apr;101(7):826-32.
- 196: Karakiewicz PI, **Suardi N**, Shariat SF.  
The search for better prognostic factors for men treated for localized prostate cancer continues.  
Eur Urol. 2008 Apr;53(4):689-90.
- 197: Karakiewicz PI, **Suardi N**, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P.  
Neoadjuvant suture induction therapy may effectively down-stage renal cell carcinoma arterial thrombi.  
Eur Urol. 2008 Apr;53(4):845-8.
- 198: Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, **Suardi N**, Saad F, Karakiewicz PI.  
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.  
J Clin Oncol. 2008 Mar 20;26(9):1526-31.
- 199: **Suardi N**, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, Correa R, Montorsi F, Graefen M, Huland H, Klein EA, Karakiewicz PI.  
A nomogram predicting long-term biochemical recurrence after radical prostatectomy.  
Cancer. 2008 Mar 15;112(6):1254-63.
- 200: Briganti A, Gallina A, **Suardi N**, Chun FK, Walz J, Heuer R, Salonia A, Haese A, Perrotte P, Valiquette L, Graefen M, Rigatti P, Montorsi F, Huland H, Karakiewicz PI.  
A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer.  
BJU Int. 2008 Mar;101(5):556-60.
- 201: Salonia A, Gallina A, Zanni G, Briganti A, Dehò F, Saccà A, **Suardi N**, Barbieri L, Guazzoni G, Rigatti P, Montorsi F. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy.  
Eur Urol. 2008 Mar;53(3):564-70.
- 202: Karakiewicz PI, Chun FK, Gallina A, **Suardi N**, Briganti A, Erbersdobler A, Schlomm T, Walz J, Currilin E, Michl U, Haese A, Arjane P, Heinzer H, Graefen M, Huland H.  
Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum.  
J Endourol. 2008 Mar;22(3):533-8.
- 203: Bhojani N, Perrotte P, Jeldres C, **Suardi N**, Hutterer G, Shariat SF, Karakiewicz PI.  
The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. J Sex Med. 2008 Mar;5(3):668-76.
- 204: Walz J, **Suardi N**, Hutterer GC, Perrotte P, Gallina A, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI.  
Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population.  
J Endourol. 2008 Feb;22(2):369-76.

205: Walz J, Perrotte P, **Suardi N**, Hutterer G, Jeldres C, Bénard F, Valiquette L, Graefen M, Montorsi F, Karakiewicz PI.

Baseline prevalence of erectile dysfunction in a prostate cancer screening population.  
J Sex Med. 2008 Feb;5(2):428-35.

206: Walz J, Perrotte P, Hutterer G, **Suardi N**, Jeldres C, Bénard F, Valiquette L, Karakiewicz PI.

Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men.  
BJU Int. 2007 Dec;100(6):1307-11.

207: Chun FK, **Suardi N**, Perrotte P, Lebeau T, Guay JP, Benayoun S, Ramirez A, Bénard F, McCormack M, Valiquette L, Karakiewicz P.

Screening men for prostate cancer and colorectal cancer: is practice evidence-based?  
Can J Urol. 2007 Dec;14(6):3727-33.

208: Briganti A, Chun FK, **Suardi N**, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI.

Prostate volume and adverse prostate cancer features: fact not artifact.  
Eur J Cancer. 2007 Dec;43(18):2669-77.

209: Briganti A, Fabbri F, Salonia A, Gallina A, Chun FK, Dehò F, Zanni G, **Suardi N**, Karakiewicz PI, Rigatti P, Montorsi F.

Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy.  
Eur Urol. 2007 Sep;52(3):702-7.

210 Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, Antebi E, Shariat SF, **Suardi N**, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F.

Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.  
Int J Cancer. 2007 Aug 15;121(4):791-5.

211: Scattoni V, Picchio M, **Suardi N**, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F.

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.  
Eur Urol. 2007 Aug;52(2):423-9.

212: Gallina A, Karakiewicz PI, Chun FK, Briganti A, Graefen M, Montorsi F, Walz J, Jeldres C, Erbersdobler A, Salonia A, Suardi N, Dehò F, Schlomm T, Scattoni V, Haese A, Heinzer H, Valiquette L, Rigatti P, Huland H. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer.

BJU Int. 2007 Jun;99(6):1404-8.

213: Hutterer G, Perrotte P, Gallina A, Walz J, Jeldres C, Traumann M, **Suardi N**, Saad F, Bénard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI.

Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.  
Eur J Cancer. 2007 May;43(7):1180-7.

214: Briganti A, Chun FK, Salonia A, Zanni G, Gallina A, Dehò F, **Suardi N**, Da Pozzo LF, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI.

A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer.  
Eur Urol. 2007 Jan;51(1):112-9.



- 215: Colombo R, Naspro R, Salonia A, Montorsi F, Raber M, **Suardi N**, Saccà A, Rigatti P.  
Radical prostatectomy after previous prostate surgery: clinical and functional outcomes.  
J Urol. 2006 Dec;176(6 Pt 1):2459-63.
- 216: Briganti A, Chun FK, Salonia A, **Suardi N**, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI.  
Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer.  
Eur Urol. 2006 Nov;50(5):1006-13.
- 217: Naspro R, **Suardi N**, Salonia A, Scattoni V, Guazzoni G, Colombo R, Cestari A, Briganti A, Mazzoccoli B, Rigatti P, Montorsi F.  
Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up.  
Eur Urol. 2006 Sep;50(3):563-8.
- 218: Salonia A, **Suardi N**, Crescenti A, Colombo R, Rigatti P, Montorsi F.  
General versus spinal anesthesia with different forms of sedation in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study.  
Int J Urol. 2006 Sep;13(9):1185-90.
- 219: Salonia A, **Suardi N**, Naspro R, Mazzoccoli B, Zanni G, Gallina A, Bua L, Scattoni V, Rigatti P, Montorsi F.  
Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis.  
Urology. 2006 Aug;68(2):302-6.
- 220: Montorsi F, Salonia A, **Suardi N**, Gallina A, Zanni G, Briganti A, Deho' F, Naspro R, Farina E, Rigatti P.  
Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy.  
Eur Urol. 2005 Dec;48(6):938-45.
- 221: Naspro R, Salonia A, Cestari A, Guazzoni G, **Suardi N**, Colombo R, Rigatti P, Montorsi F.  
A critical analysis of laser prostatectomy in the management of benign prostatic hyperplasia.  
BJU Int. 2005 Oct;96(5):736-9.
- 222: Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, **Suardi N**, Cestari A, Montorsi P, Rigatti P.  
Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience.  
Eur Urol. 2005 May;47(5):612-21. Epub 2005 Jan 26. Review. PubMed PMID: 15826752.
- 223: Salonia A, **Suardi N**, Crescenti A, Zanni G, Fantini GV, Gallina A, Ghezzi M, Colombo R, Montorsi F, Rigatti P.  
Pfannenstiel versus vertical laparotomy in patients undergoing radical retropubic prostatectomy with spinal anesthesia: results of a prospective, randomized trial.  
Eur Urol. 2005 Feb;47(2):202-8. PubMed PMID: 15661415.
- 224: Salonia A, Briganti A, Montorsi P, Maga T, Dehò F, Zanni G, Mazzoccoli B, **Suardi N**, Rigatti P, Montorsi F.  
Safety and tolerability of oral erectile dysfunction treatments in the elderly.  
Drugs Aging. 2005;22(4):323-38. PubMed PMID: 15839721.

225: Montorsi F, Naspro R, Salonia A, **Suardi N**, Briganti A, Zanoni M, Valenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004 Nov;172(5 Pt 1):1926-9. PubMed PMID: 15540757.

226: Salonia A, Crescenti A, **Suardi N**, Memmo A, Naspro R, Bocciardi AM, Colombo R, Da Pozzo LF, Rigatti P, Montorsi F.  
General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study. Urology. 2004 Jul;64(1):95-100. PubMed PMID: 15245943.

227: Briganti A, Salonia A, Gallina A, **Suardi N**, Rigatti P, Montorsi F.  
Emerging oral drugs for erectile dysfunction. Expert Opin Emerg Drugs. 2004 May;9(1):179-89. Review. PubMed PMID: 15155143.

---

Genova, 01/11/2019

